Medical and Pharmaceutical

More than 480 residents participated in the American Lung Association's annual event

The deal could provide shareholders with an extra $0.70 per share if company's drug gains regulatory approval in Europe

It features the state's first AI-powered lung nodule detection program

"A truly MONUMENTAL day," said a representative from the IU Simon Comprehensive Cancer Center

Taletrectinib is the most advanced drug in the company's pipeline

The company's product for relapsing forms of multiple sclerosis (RMS), is its primary source of its most recent success

Trump imposed 25 per cent duties on imports from Mexico and Canada, set to take effect in March

Nearly half of the 28,400 additional cancer deaths linked to deprivation are due to lung cancer

Pulmonx achieved USD$83.8 million in worldwide revenue, reflecting a robust 22 per cent growth over 2023

In a clinical trial with blood from 83 patients, the test identified 100 per cent of EGFR gene mutations

A persistent cough and breathlessness while climbing stairs prompted him to visit the hospital

It is the last Canadian province without a program for catching the disease

This new screening device is the product of a 3-year study from Cranfield University scholars

The stock was up by about 200% during early trading hours

The investigators examined data from more than 7,000 patients over an 11-year period to make this determination

About 372,000 people are diagnosed with SCLC annually worldwide

It was trained by examining over 1,500 CT scans

It will be issued within 3 months provided that there are no opposition filings made by third parties

The Canadian Cancer Society reports that healthcare professionals diagnose over 100 types of cancer-related diseases each year

'Limertinib' targets non-small cell lung cancer with a particular mutation that is prevalent in Asian patients

The annual J.P. Morgan Healthcare Conference is held in San Francisco

Non-small cell lung cancer constitutes 85 per cent of all lung cancer cases

Shareholders are having a pretty stellar Monday with the immense gains

British researchers just published an extensive study on the tissue biopsy in Nature Cancer

The study showed that Sana's hypoimmune (HIP) modified pancreatic islet cells could successfully evade the patient's immune system

It was completed by the University of St Andrews and published in the PLOS One journal on Wednesday

The stock rose by 146% in early morning trading on the Nasdaq

The biopharma operator's 'HT-001" drug was highly successful in alleviating skin issues caused by a cancer treatment

Innovent Biologics will receive up to US$1 billion in milestone payments and royalties

An absence of data has rendered the announcement questionable

The year’s economic landscape as 2024 comes to a close demonstrates the resilience and adaptability of key sectors

The biotech operator can develop and commercialize Jemincare's food allergy medication throughout most of the world

KB707 demonstrated a 27% objective response rate and 73% disease control rate

More treatment innovation just in time for the holidays

The stock went up by over 185% after the LOI was announced

Denifanstat received FDA Breakthrough Therapy designation for metabolic dysfunction-associated steatohepatitis

This UK oncology company was spun out from the University of York's Department of Biology

It will examine the efficacy of 'eftilagimod alfa' in conjunction with Merck's Keytruda drug and chemo

Usage of the therapeutic resulted in unhealthy levels of transaminases (liver enzymes) in participants

It is not the first pee test used to help diagnose the disease, but it is the first of its kind